Core Insights - Scilex Holding Company has successfully closed the second tranche of its strategic investment in Datavault AI, acquiring shares valued at approximately $583.3 million based on the closing price of Datavault's common stock [1][5]. Company Overview - Scilex is focused on acquiring, developing, and commercializing non-opioid pain management products for treating acute and chronic pain, as well as neurodegenerative and cardiometabolic diseases [3][4]. - The company has several commercial products, including ZTlido® for neuropathic pain, ELYXYB® for acute migraine treatment, and Gloperba® for gout flare prophylaxis [3][4]. Product Development - Scilex has three product candidates in development: - SP-102, a viscous gel for lumbosacral radicular pain, which has completed Phase 3 studies and received Fast Track status from the FDA [4]. - SP-103, a next-generation lidocaine topical system for acute pain, which has recently completed a Phase 2 trial [4]. - SP-104, a low-dose naltrexone for fibromyalgia treatment, is also under development [6]. Strategic Investment - The strategic investment in Datavault AI involves the purchase of a pre-funded warrant for 263,914,094 shares of Datavault AI common stock, with the transaction being approved by Datavault's stockholders [5]. - Both companies plan to enhance collaboration to drive growth in Real World Asset tokenization starting in 2026 [5]. Datavault AI Overview - Datavault AI specializes in AI-driven data experiences and asset monetization, offering solutions across various industries, including biotech, fintech, and healthcare [7]. - The company’s platform includes technologies for audio transmission and high-performance computing, enabling secure monetization and data analytics [7].

Core Insights - Datavault AI has successfully closed the second tranche of equity financing with Scilex Holding Company, issuing a pre-funded warrant for approximately 263.91 million shares in exchange for about 1,237.6 Bitcoin [1][8] - The strategic investment aims to provide growth capital to enhance Datavault's digital asset reserves, accelerate supercomputing infrastructure, and support platform expansion [2] - Datavault has granted Scilex an exclusive worldwide license for its AI-driven technology tailored for the biotech and biopharma industry, which includes a nonrefundable upfront license fee totaling $10 million and potential sales milestone payments of up to $2.55 billion [3][4] Financial Details - The initial tranche of Scilex's investment was closed on September 26, 2025, valued at approximately $8 million in Bitcoin [1][8] - The second tranche involves a purchase of approximately 1,237.6 Bitcoin, reflecting a significant investment in Datavault's future growth [1][8] - Scilex will pay the upfront license fee in four equal installments of $2.5 million, with the first payment due by December 31, 2025 [4] Leadership Commentary - Scilex CEO Henry Ji expressed confidence in the collaboration, highlighting the alignment of Datavault's technologies with the biotech sector's needs for advanced data analytics and supercomputing power [5] - Datavault AI CEO Nathanial Bradley welcomed Scilex as a major stockholder, emphasizing the shared vision for leveraging digital assets to capture market share in the biotech sector [5] Company Overview - Datavault AI specializes in AI-driven data experiences and asset monetization in the Web 3.0 environment, offering solutions across various industries including biotech, fintech, and healthcare [6][7] - The company's technology suite includes patented technologies for audio transmission and high-performance computing solutions [6][7]

Core Insights - Datavault AI Inc. has signed a 5-year lease for approximately 23,037 rentable square feet at One Commerce Square in Philadelphia, establishing its permanent corporate headquarters [1][2] - The lease includes a base monthly rent of around $48,000 with modest annual increases, supporting the company's growth strategy in AI, data tokenization, and digital credentialing technologies [2][4] - The new headquarters will serve as a central hub for development, sales, and operations, facilitating enterprise integrations and client engagement [4] Company Overview - Datavault AI is a leader in data monetization, credentialing, and digital engagement technologies, focusing on AI-driven data experiences and asset valuation in the Web 3.0 environment [5] - The company's cloud-based platform offers solutions across various industries, including sports, entertainment, biotech, education, fintech, real estate, healthcare, and energy [5] - Datavault AI's technology suite includes patented technologies for audio transmission and solutions for experiential data perception, valuation, and secure monetization [5]

Core Viewpoint - Datavault AI has filed a lawsuit against Wolfpack Research and its founder Dan David for a defamatory short report that allegedly harmed the company and its shareholders [1][2][3] Group 1: Lawsuit Details - The lawsuit seeks redress for a malicious short report released on October 31, 2025, which contained false and misleading accusations against Datavault AI and its personnel [1][2] - The report's disregard for Datavault's public filings and omission of critical context resulted in direct harm to the company and its shareholders [2] Group 2: Company Response - Nathaniel Bradley, CEO of Datavault AI, stated that the company and its shareholders have been harmed by Wolfpack's actions and emphasized the commitment to hold the defendants accountable in court [3] - Despite the distraction caused by the lawsuit, the company remains focused on generating revenue and driving shareholder value [3] Group 3: Company Overview - Datavault AI (Nasdaq: DVLT) specializes in AI-driven data experiences, asset valuation, and monetization in the Web 3.0 environment [4] - The company's cloud-based platform offers solutions across various industries, including sports, entertainment, biotech, education, fintech, real estate, healthcare, and energy [4] - Datavault AI's technology suite includes patented technologies for audio transmission and secure monetization of data, emphasizing responsible AI practices [4]

Core Insights - Datavault AI Inc. has announced a definitive acquisition agreement to acquire API Media, enhancing its technology culture and capabilities in data activation and monetization [1][2] - The acquisition aims to strengthen Datavault's proprietary data-monetization ecosystem and expand its recurring-revenue base [2][3] - API Media's expertise in audio-visual technologies and IT services for large events will complement Datavault's offerings, particularly in AI and analytics [2][3] Company Overview - Datavault AI is a leader in data tokenization and monetization technologies, focusing on AI-driven data experiences in the Web 3.0 environment [3] - The company provides a cloud-based platform with solutions across various industries, including sports, entertainment, biotech, and healthcare [3] - Datavault's technology suite includes patented technologies for audio transmission and data management, enabling secure monetization and compliance [3] Strategic Implications - The acquisition of API Media is expected to accelerate Datavault's growth trajectory and enhance its market share in data-driven media and marketing [2][3] - The integration will provide Datavault with expanded expertise in digital media operations, audience intelligence, and revenue analytics [2][3] - This move positions Datavault as a global leader in data monetization and AI-enabled experiential events, creating new revenue streams for enterprise clients [2][3]

Core Insights - Datavault AI Inc. has appointed Pete Scobell as Vice President of Global Security to enhance its security operations and support its initiatives, including the Anti-Stolen Valor program and the International Elements Exchange launch [1][2][3] Company Developments - The Anti-Stolen Valor initiative aims to honor military service and promote integrity and accountability within a data-driven ecosystem, aligning with Datavault's mission of merging value creation with national service principles [2] - Scobell's extensive background as a U.S. Navy SEAL veteran is expected to bring discipline and precision to Datavault's operations, particularly in real-world asset logistics [3][4] Strategic Focus - The company emphasizes the importance of moral protection alongside physical security, aiming to set a new global standard for accountability and trust in its operations [4] - Datavault AI is focused on leveraging its cloud-based platform for AI-driven data experiences, valuation, and monetization across various industries, including sports, entertainment, biotech, and fintech [5]

Core Points - Datavault AI Inc. has regained compliance with Nasdaq Listing Rule 5550(a)(2) regarding the minimum bid price requirement for its common stock [1][2] - The company's common stock maintained a closing bid price of at least $1.00 per share for ten consecutive trading days from September 26, 2025, to October 9, 2025 [2] - The resolution of this compliance issue highlights Datavault AI's commitment to maintaining its listing status and delivering value to shareholders [3] Company Overview - Datavault AI Inc. specializes in secure data tokenization and Web 3.0 innovations, offering AI-driven data experiences, valuation, and monetization [1][5] - The company operates a cloud-based platform that provides solutions across various industries, including sports & entertainment, biotech, education, fintech, real estate, healthcare, and energy [5] - Datavault AI's technology suite includes patented technologies in its Acoustic Science Division and high-performance computing solutions in its Data Science Division [5]

Core Insights - Datavault AI Inc. has successfully converted long-term notes with an original face value of $13.3 million, significantly strengthening its balance sheet [1][2] - The conversion of these notes is viewed as a strategic milestone that supports the accelerated launch of independent data exchanges (IDEs) and the development of supercomputing capabilities in collaboration with IBM [2] - The company recently secured a $150 million strategic equity investment in Bitcoin from Scilex, a Nasdaq-listed biotech company, which aligns with Datavault AI's focus on the biotech sector as a primary target market [2] Company Overview - Datavault AI is a leader in AI-driven data experiences, focusing on the valuation and monetization of assets within the Web 3.0 environment [3] - The company's cloud-based platform offers comprehensive solutions across various industries, including sports & entertainment, biotech, education, fintech, real estate, healthcare, and energy [3] - Datavault AI's technology suite includes patented technologies for audio transmission and high-performance computing solutions for data perception, valuation, and secure monetization [3] - The Information Data Exchange (IDE) enables the creation of Digital Twins and the licensing of name, image, and likeness (NIL), promoting responsible AI practices [3]

Core Viewpoint - Scilex Holding Company has completed the initial tranche of a $150 million investment in Datavault AI Inc., acquiring 15 million shares at an effective price of $0.5378 per share, with potential for additional shares pending stockholder approval [1]. Company Overview - Scilex is focused on acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain, as well as neurodegenerative and cardiometabolic diseases [3][5]. - The company targets high unmet needs in the market with its non-opioid therapies, aiming to improve patient outcomes [3]. Commercial Products - Scilex's commercial products include: - ZTlido® (lidocaine topical system) 1.8%, approved for neuropathic pain relief [3]. - ELYXYB®, an FDA-approved oral solution for acute migraine treatment [3]. - Gloperba®, the first liquid oral version of colchicine for gout flare prophylaxis [3]. Product Candidates - Scilex has three product candidates in development: - SP-102 (SEMDEXA), a viscous gel for epidural injections to treat sciatica, which has completed Phase 3 studies and received Fast Track status from the FDA [4]. - SP-103, a next-generation lidocaine topical system for acute pain, recently completed a Phase 2 trial and has also received Fast Track status [4]. - SP-104, a low-dose naltrexone hydrochloride for fibromyalgia treatment [4]. Investment Details - The initial tranche of the investment in Datavault AI Inc. involves the acquisition of 15 million shares, with the potential for up to 278,914,094 shares in total, subject to stockholder approval [1]. - The effective purchase price for the shares is $0.5378, with adjustments possible for stock splits [1].

Core Viewpoint - Datavault AI Inc. clarifies that recent insider stock sales were made to cover tax obligations related to the vesting of incentive share grants, and the reporting officers have not sold any of their shares [1][2]. Company Overview - Datavault AI Inc. (Nasdaq: DVLT) specializes in AI-driven data monetization and operates a cloud-based platform that offers solutions across various industries, including sports, biotech, education, and healthcare [3]. - The company’s technology suite includes patented technologies in its Acoustic Science Division and leverages high-performance computing in its Data Science Division to provide secure monetization and valuation of data [3]. Financial Performance - In Q2 2025, Datavault AI reported recognized revenue of $1.7 million, reflecting a significant year-over-year growth of 467% [7]. - The company also secured a $2.5 million licensing deal with Nyiax during the same quarter [7].